STOCK TITAN

Edwards Lifesciences (EW) executive vests performance units and withholds shares for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Daveen Chopra reported routine equity compensation activity involving performance-based restricted stock units. Chopra exercised performance rights covering 13,583 shares of common stock, linked to awards granted on May 11, 2023 with three-year performance vesting.

In connection with vesting, 7,538 shares of common stock were disposed of to cover tax obligations at a price of $79.96 per share, rather than through an open-market sale. Following these transactions, Chopra holds 45,824 shares of Edwards Lifesciences common stock directly.

The board’s Compensation and Governance Committee previously determined that 167.70% of the target number of performance-based units would vest as of May 11, 2026, and this Form 4 reflects the resulting share delivery and tax-withholding disposition.

Positive

  • None.

Negative

  • None.
Insider Chopra Daveen
Role CVP, TMTT & Surgical
Type Security Shares Price Value
Exercise Performance Rights 13,583 $0.00 --
Exercise Common Stock 13,583 $0.00 --
Tax Withholding Common Stock 7,538 $79.96 $603K
Holdings After Transaction: Performance Rights — 0 shares (Direct, null); Common Stock — 53,362 shares (Direct, null)
Footnotes (1)
  1. On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. These Performance Rights expire on May 10, 2030.
Performance shares exercised 13,583 shares Common stock from performance rights exercised on May 11, 2026
Shares withheld for taxes 7,538 shares Tax-withholding disposition at $79.96 per share
Tax-withholding price $79.96 per share Price used for 7,538-share tax payment in stock
Shares held after transactions 45,824 shares Direct common stock ownership following Form 4 transactions
Performance vesting factor 167.70% Portion of target performance-based units determined to vest
Performance rights expiration May 10, 2030 Expiration date of the performance rights award
Performance Rights financial
"These Performance Rights expire on May 10, 2030."
Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.
restricted stock units financial
"granted a target number of shares covered by restricted stock units with performance-based vesting requirements"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance-based vesting requirements financial
"restricted stock units with performance-based vesting requirements over a three-year performance period"
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
derivative exercise/conversion financial
"Exercise or conversion of derivative security"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chopra Daveen

(Last)(First)(Middle)
ONE EDWARDS WAY

(Street)
IRVINE CALIFORNIA 92614

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CVP, TMTT & Surgical
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/11/2026M13,583(1)A$0(1)53,362D
Common Stock05/11/2026F7,538D$79.9645,824D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Rights(1)05/11/2026M13,58305/11/2026 (2)Common Stock13,583$0.00000.0000D
Explanation of Responses:
1. On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.
2. These Performance Rights expire on May 10, 2030.
Remarks:
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Edwards Lifesciences (EW) report for Daveen Chopra?

Edwards Lifesciences reported that executive Daveen Chopra exercised performance rights for 13,583 shares of common stock and had 7,538 shares withheld to cover taxes. These actions reflect routine equity compensation vesting, not open-market buying or selling.

How many Edwards Lifesciences (EW) shares does Daveen Chopra own after this Form 4?

After the reported transactions, Daveen Chopra directly holds 45,824 shares of Edwards Lifesciences common stock. This figure reflects the net position following the performance rights exercise and the related 7,538-share tax-withholding disposition.

What performance award vested for Edwards Lifesciences (EW) executive Daveen Chopra?

Chopra’s award was a grant of restricted stock units with performance-based vesting over three years. The board’s Compensation and Governance Committee determined that 167.70% of the target units vested as of May 11, 2026, resulting in 13,583 shares delivered.

Was the Edwards Lifesciences (EW) Form 4 for Daveen Chopra an open-market stock sale?

No. The filing shows a tax-withholding disposition of 7,538 shares at $79.96 per share to satisfy tax obligations on vested performance rights, rather than a discretionary open-market sale of shares.